TapewireFind a company

person · Reporting owner

Beaver Sandra

Disclosed activity across 2 companies

Tapewire entity
44900
SEC CIK
0001944884

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Evolus, Inc.EOLS · Entity 5341Chief Financial OfficerMay 13, 2025May 14, 2025
TANDEM DIABETES CARE INCTNDM · Entity 4682DirectorMay 20, 2026May 22, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Evolus, Inc.

Report date May 13, 2025 · Filed May 14, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect167,089 Reported balance After 2025-05-13 transaction · row 1
1 source row

Row 1 · 2025-05-13 · Sale · Disposed 6,494 · Balance 167,089

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain restricted stock units.

TANDEM DIABETES CARE INC

Report date May 20, 2026 · Filed May 22, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Restricted Stock UnitSEC Table II · derivative / convertible securityDirect5,110 Reported balance After 2026-05-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-05-20 · Grant · Acquired 5,110 · Balance 5,110

F1: Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F2: Such RSUs were granted to the Reporting Person on May 20, 2026, and will vest on the one-year anniversary thereof, subject to the terms of the 2023 Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F2: Such RSUs were granted to the Reporting Person on May 20, 2026, and will vest on the one-year anniversary thereof, subject to the terms of the 2023 Plan.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 20, 2026 Filed May 22, 2026 20:10 UTC TANDEM DIABETES CARE INC TNDM · Entity 4682 GrantRestricted Stock Unit · Derivative 5,110 $0.00 $0.00
Disclosure

SEC source: 0001438133-26-000077 · wk-form4_1779480632.xml · derivative · entry 1

Beaver Sandra · CIK 0001944884 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,110

Underlying: Common Stock · 5,110 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock units (RSU) represents a contingent right to receive either one share of the Issuers common stock or cash in lieu thereof, at the Issuers discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F2 · derivative.exercise_date: Such RSUs were granted to the Reporting Person on May 20, 2026, and will vest on the one-year anniversary thereof, subject to the terms of the 2023 Plan.

F2 · derivative.expiration_date: Such RSUs were granted to the Reporting Person on May 20, 2026, and will vest on the one-year anniversary thereof, subject to the terms of the 2023 Plan.

Read SEC document
November 07, 2025 Filed Nov 25, 2025 21:10 UTC TANDEM DIABETES CARE INC TNDM · Entity 4682 GrantRestricted Stock Unit · Derivative 20,242 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000221 · wk-form4_1764105030.xml · derivative · entry 1

Beaver Sandra · CIK 0001944884 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,242

Underlying: Common Stock · 20,242 shares

Expires not disclosed

F1 · security: Awarded on November 7, 2025 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F3 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 11/15/2026, and the remaining shares shall vest in two (2) equal annual installments thereafter.

F3 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 11/15/2026, and the remaining shares shall vest in two (2) equal annual installments thereafter.

Read SEC document
May 13, 2025 Filed May 14, 2025 23:27 UTC Evolus, Inc. EOLS · Entity 5341 SaleCommon Stock 6,494 $10.02 $65,069.88
Disclosure

SEC source: 0001570562-25-000080 · wk-form4_1747265253.xml · nonDerivative · entry 1

Beaver Sandra · CIK 0001944884 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 167,089

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain restricted stock units.

Read SEC document
March 18, 2025 Filed Mar 20, 2025 22:27 UTC Evolus, Inc. EOLS · Entity 5341 SaleCommon Stock 8,996 $13.26 $119,242.88
Disclosure

SEC source: 0001570562-25-000053 · wk-form4_1742509639.xml · nonDerivative · entry 1

Beaver Sandra · CIK 0001944884 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 173,583

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units.

F2 · price: The shares were sold in multiple trades at prices ranging from $13.185 to $13.256. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 22:54 UTC Evolus, Inc. EOLS · Entity 5341 GrantStock Option (Right to Buy) · Derivative 50,813 $0.00 Strike: $13.58 $0.00
Disclosure

SEC source: 0001570562-25-000043 · wk-form4_1741733687.xml · derivative · entry 3

Beaver Sandra · CIK 0001944884 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,813

Underlying: Common Stock · 50,813 shares

Expires 2035-03-07

F4 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of March 7, 2025, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 22:54 UTC Evolus, Inc. EOLS · Entity 5341 GrantPerformance Restricted Stock Units · Derivative 35,663 $0.00 $0.00
Disclosure

SEC source: 0001570562-25-000043 · wk-form4_1741733687.xml · derivative · entry 2

Beaver Sandra · CIK 0001944884 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,663

Underlying: Common Stock · 35,663 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance-based restricted stock unit ("PSU") represents the right to receive, following vesting, a number of shares of common stock of the issuer up to 200% of the number of PSUs.

F3 · derivative.exercise_date: The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metrics, as approved by the Issuer's Compensation Committee, over a two-year performance period. Subject to the Issuer's compensation committee certifying the underlying performance metrics, 100% of the PSUs will vest on March 7, 2028 in each case subject to time based service requirements and continuous employment with the Issuer through the vesting dates.

F3 · derivative.expiration_date: The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metrics, as approved by the Issuer's Compensation Committee, over a two-year performance period. Subject to the Issuer's compensation committee certifying the underlying performance metrics, 100% of the PSUs will vest on March 7, 2028 in each case subject to time based service requirements and continuous employment with the Issuer through the vesting dates.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 22:54 UTC Evolus, Inc. EOLS · Entity 5341 GrantCommon Stock 35,663 $0.00 $0.00
Disclosure

SEC source: 0001570562-25-000043 · wk-form4_1741733687.xml · nonDerivative · entry 1

Beaver Sandra · CIK 0001944884 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 182,579

F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of March 7, 2025, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.

Read SEC document
December 23, 2024 Filed Dec 26, 2024 22:28 UTC Evolus, Inc. EOLS · Entity 5341 SaleCommon Stock 1,586 $10.85 $17,211.11
Disclosure

SEC source: 0001570562-24-000139 · wk-form4_1735252093.xml · nonDerivative · entry 1

Beaver Sandra · CIK 0001944884 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 146,916

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.

Read SEC document
September 06, 2024 Filed Sep 7, 2024 01:45 UTC Evolus, Inc. EOLS · Entity 5341 SaleCommon Stock 3,276 $14.98 $49,074.48
Disclosure

SEC source: 0001570562-24-000121 · wk-form4_1725673547.xml · nonDerivative · entry 1

Beaver Sandra · CIK 0001944884 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,502

F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

Read SEC document
May 10, 2024 Filed May 15, 2024 00:55 UTC Evolus, Inc. EOLS · Entity 5341 SaleCommon Stock 2,423 $12.72 $30,814.26
Disclosure

SEC source: 0001570562-24-000084 · wk-form4_1715734540.xml · nonDerivative · entry 1

Beaver Sandra · CIK 0001944884 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 151,778

F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F2 · price: The shares were sold in multiple trades at prices ranging from $12.51 to $13.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
March 19, 2024 Filed Mar 21, 2024 22:09 UTC Evolus, Inc. EOLS · Entity 5341 SaleCommon Stock 5,672 $13.92 $78,978.06
Disclosure

SEC source: 0001570562-24-000054 · wk-form4_1711058949.xml · nonDerivative · entry 1

Beaver Sandra · CIK 0001944884 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,201

F1 · kind: The sales reported on this Form 4 were mandated by the Issuer pursuant to Restricted Stock Unit Agreements requiring the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction, and does not represent a discretionary trade by the reporting person.

F2 · price: The shares were sold in multiple trades at prices ranging from $13.555 to $14.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
February 22, 2024 Filed Feb 24, 2024 01:27 UTC Evolus, Inc. EOLS · Entity 5341 SaleCommon Stock 1,821 $13.08 $23,820.87
Disclosure

SEC source: 0001570562-24-000029 · wk-form4_1708738037.xml · nonDerivative · entry 2

Beaver Sandra · CIK 0001944884 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 159,873

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the PSUs.

Read SEC document
February 21, 2024 Filed Feb 24, 2024 01:27 UTC Evolus, Inc. EOLS · Entity 5341 GrantCommon Stock 13,115 $0.00 $0.00
Disclosure

SEC source: 0001570562-24-000029 · wk-form4_1708738037.xml · nonDerivative · entry 1

Beaver Sandra · CIK 0001944884 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 161,694

F1 · shares: Represents shares issuable on settlement of performance restricted stock units ("PSUs") granted to the reporting person in January 2023. The Issuer's Compensation Committee certified that the reporting person had achieved the set corporate development goal as of December 20, 2023. One-third of the PSU (4,372 shares) was delivered on February 21, 2024 after certification of the milestone being achieved. The remaining two-thirds will vest annually on the anniversary of December 20, 2023 provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.

Read SEC document
February 07, 2024 Filed Feb 9, 2024 23:36 UTC Evolus, Inc. EOLS · Entity 5341 GrantStock Option (Right to Buy) · Derivative 47,337 $0.00 Strike: $13.15 $0.00
Disclosure

SEC source: 0001570562-24-000018 · wk-form4_1707521768.xml · derivative · entry 3

Beaver Sandra · CIK 0001944884 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,337

Underlying: Common Stock · 47,337 shares

Expires 2034-02-07

F4 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of February 7, 2024, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.

Read SEC document
February 07, 2024 Filed Feb 9, 2024 23:36 UTC Evolus, Inc. EOLS · Entity 5341 GrantPerformance Restricted Stock Units · Derivative 17,606 $0.00 $0.00
Disclosure

SEC source: 0001570562-24-000018 · wk-form4_1707521768.xml · derivative · entry 2

Beaver Sandra · CIK 0001944884 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,606

Underlying: Common Stock · 17,606 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance-based restricted stock unit (PSU) represents the right to receive, following vesting, a number of shares of common stock of the issuer up to 200% of the number of PSUs.

F3 · derivative.exercise_date: The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metrics, as approved by the Issuer's Compensation Committee, over a two-year performance period. Subject to the Issuer's compensation committee certifying the underlying performance metrics, 50% of the PSUs earned will vest on February 7, 2026 and the remaining 50% of the PSUs will vest on February 7, 2027, in each case subject to time based service requirements and continuous employment with the Issuer through the vesting dates.

F3 · derivative.expiration_date: The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metrics, as approved by the Issuer's Compensation Committee, over a two-year performance period. Subject to the Issuer's compensation committee certifying the underlying performance metrics, 50% of the PSUs earned will vest on February 7, 2026 and the remaining 50% of the PSUs will vest on February 7, 2027, in each case subject to time based service requirements and continuous employment with the Issuer through the vesting dates.

Read SEC document
February 07, 2024 Filed Feb 9, 2024 23:36 UTC Evolus, Inc. EOLS · Entity 5341 GrantCommon Stock 35,211 $0.00 $0.00
Disclosure

SEC source: 0001570562-24-000018 · wk-form4_1707521768.xml · nonDerivative · entry 1

Beaver Sandra · CIK 0001944884 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 148,579

F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of February 7, 2024, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.

Read SEC document
September 06, 2023 Filed Sep 9, 2023 00:54 UTC Evolus, Inc. EOLS · Entity 5341 SaleCommon Stock 3,178 $9.70 $30,826.60
Disclosure

SEC source: 0001570562-23-000106 · wk-form4_1694220838.xml · nonDerivative · entry 1

Beaver Sandra · CIK 0001944884 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 113,368

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units.

Read SEC document
August 16, 2023 Filed Aug 17, 2023 00:25 UTC Evolus, Inc. EOLS · Entity 5341 SaleCommon Stock 2,211 $10.27 $22,706.97
Disclosure

SEC source: 0001570562-23-000099 · wk-form4_1692231918.xml · nonDerivative · entry 2

Beaver Sandra · CIK 0001944884 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 116,546

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the PSUs.

Read SEC document
August 14, 2023 Filed Aug 17, 2023 00:25 UTC Evolus, Inc. EOLS · Entity 5341 GrantCommon Stock 19,672 $0.00 $0.00
Disclosure

SEC source: 0001570562-23-000099 · wk-form4_1692231918.xml · nonDerivative · entry 1

Beaver Sandra · CIK 0001944884 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 118,757

F1 · shares: Represents shares issuable on settlement of performance restricted stock units ("PSUs") granted to the reporting person in January 2023. On August 14, 2023, the Issuer's Compensation Committee certified that the reporting person had achieved the set corporate development goal as of May 9, 2023. One-third of the PSU (6,557 shares) was vested and delivered immediately upon certification of the goal achievement. The remaining two-thirds will vest annually on the anniversary of May 9, 2023 provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.

Read SEC document
January 25, 2023 Filed Jan 28, 2023 00:24 UTC Evolus, Inc. EOLS · Entity 5341 GrantStock Option (Right to Buy) · Derivative 85,670 $0.00 Strike: $11.04 $0.00
Disclosure

SEC source: 0001570562-23-000010 · wf-form4_167486545975097.xml · derivative · entry 2

Beaver Sandra · CIK 0001944884 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,670

Underlying: Common Stock · 85,670 shares

Expires 2033-01-25

F2 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of January 25, 2023, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.

Read SEC document
January 25, 2023 Filed Jan 28, 2023 00:24 UTC Evolus, Inc. EOLS · Entity 5341 GrantCommon Stock 62,642 $0.00 $0.00
Disclosure

SEC source: 0001570562-23-000010 · wf-form4_167486545975097.xml · nonDerivative · entry 1

Beaver Sandra · CIK 0001944884 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,085

F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of January 25, 2023, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.

Read SEC document
September 05, 2022 Filed Sep 6, 2022 21:08 UTC Evolus, Inc. EOLS · Entity 5341 GrantStock Option (Right to Buy) · Derivative 169,158 $0.00 Strike: $9.06 $0.00
Disclosure

SEC source: 0001570562-22-000125 · wf-form4_166249851366040.xml · derivative · entry 2

Beaver Sandra · CIK 0001944884 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,158

Underlying: Common Stock · 169,158 shares

Expires 2032-09-05

F2 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of September 5, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.

Read SEC document
September 05, 2022 Filed Sep 6, 2022 21:08 UTC Evolus, Inc. EOLS · Entity 5341 GrantCommon Stock 36,443 $0.00 $0.00
Disclosure

SEC source: 0001570562-22-000125 · wf-form4_166249851366040.xml · nonDerivative · entry 1

Beaver Sandra · CIK 0001944884 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,443

F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of September 5, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.